Innate Pharma (IPHA) Competitors $2.04 0.00 (-0.20%) As of 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IPHA vs. OCS, NAGE, VALN, GYRE, GHRS, VIR, KURA, RLAY, BGM, and SANAShould you be buying Innate Pharma stock or one of its competitors? The main competitors of Innate Pharma include Oculis (OCS), Niagen Bioscience (NAGE), Valneva (VALN), Gyre Therapeutics (GYRE), GH Research (GHRS), Vir Biotechnology (VIR), Kura Oncology (KURA), Relay Therapeutics (RLAY), BGM Group (BGM), and Sana Biotechnology (SANA). These companies are all part of the "pharmaceutical products" industry. Innate Pharma vs. Its Competitors Oculis Niagen Bioscience Valneva Gyre Therapeutics GH Research Vir Biotechnology Kura Oncology Relay Therapeutics BGM Group Sana Biotechnology Innate Pharma (NASDAQ:IPHA) and Oculis (NASDAQ:OCS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment. Is IPHA or OCS more profitable? Innate Pharma has a net margin of 0.00% compared to Oculis' net margin of -13,958.12%. Innate Pharma's return on equity of 0.00% beat Oculis' return on equity.Company Net Margins Return on Equity Return on Assets Innate PharmaN/A N/A N/A Oculis -13,958.12%-90.31%-67.85% Does the media refer more to IPHA or OCS? In the previous week, Oculis had 1 more articles in the media than Innate Pharma. MarketBeat recorded 4 mentions for Oculis and 3 mentions for Innate Pharma. Innate Pharma's average media sentiment score of 1.27 beat Oculis' score of 1.11 indicating that Innate Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innate Pharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oculis 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, IPHA or OCS? Innate Pharma has higher revenue and earnings than Oculis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInnate Pharma$21.77M8.47-$53.53MN/AN/AOculisN/AN/A-$97.43M-$2.67-6.52 Do insiders & institutionals hold more shares of IPHA or OCS? 0.2% of Innate Pharma shares are held by institutional investors. Comparatively, 22.3% of Oculis shares are held by institutional investors. 31.9% of Innate Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more risk and volatility, IPHA or OCS? Innate Pharma has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Comparatively, Oculis has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500. Do analysts recommend IPHA or OCS? Innate Pharma currently has a consensus price target of $11.00, suggesting a potential upside of 450.00%. Oculis has a consensus price target of $35.75, suggesting a potential upside of 105.46%. Given Innate Pharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Innate Pharma is more favorable than Oculis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Innate Pharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Oculis 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryInnate Pharma beats Oculis on 10 of the 14 factors compared between the two stocks. Get Innate Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IPHA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IPHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IPHA vs. The Competition Export to ExcelMetricInnate PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$184.36M$3.12B$5.79B$10.15BDividend YieldN/A2.32%5.69%4.61%P/E RatioN/A21.3074.5925.92Price / Sales8.47258.83454.0285.55Price / CashN/A45.3337.0859.91Price / Book18.189.6112.156.29Net Income-$53.53M-$53.29M$3.28B$270.85M7 Day Performance-2.44%0.28%0.98%3.35%1 Month Performance-3.38%8.90%7.20%6.40%1 Year Performance-12.28%13.14%63.06%28.21% Innate Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IPHAInnate Pharma3.0209 of 5 stars$2.00-2.0%$11.00+450.0%-14.6%$184.36M$21.77M0.00220Positive NewsUpcoming EarningsGap DownOCSOculis3.3025 of 5 stars$17.25+0.2%$35.75+107.2%+43.5%$751.86MN/A-6.462Short Interest ↓NAGENiagen Bioscience2.0297 of 5 stars$9.45+0.4%$13.42+42.0%N/A$750.47M$99.60M45.00120Analyst DowngradeVALNValneva2.7906 of 5 stars$8.52-1.5%$15.00+76.1%+31.1%$743.27M$183.52M-8.69700Short Interest ↓Gap DownGYREGyre Therapeutics1.672 of 5 stars$7.89+2.6%$18.00+128.1%-41.1%$740.65M$105.76M789.7940News CoveragePositive NewsAnalyst RevisionGHRSGH Research2.5471 of 5 stars$13.51-4.1%$32.00+136.9%+53.3%$733.08MN/A-18.2610VIRVir Biotechnology3.25 of 5 stars$5.19-1.5%$26.80+416.4%-33.2%$732.09M$74.21M-1.30580KURAKura Oncology4.3181 of 5 stars$8.14-1.0%$24.10+196.1%-55.6%$713.47M$53.88M-3.60130Positive NewsInsider TradeRLAYRelay Therapeutics2.9131 of 5 stars$4.06-1.5%$17.50+331.0%-46.9%$710.34M$10.01M-2.08330Positive NewsBGMBGM Group0.7649 of 5 stars$7.33+1.1%N/A+18.6%$704.86M$25.10M0.00298SANASana Biotechnology3.3586 of 5 stars$3.00+1.4%$8.00+166.7%-31.9%$703.91MN/A-2.83380Positive News Related Companies and Tools Related Companies OCS Alternatives NAGE Alternatives VALN Alternatives GYRE Alternatives GHRS Alternatives VIR Alternatives KURA Alternatives RLAY Alternatives BGM Alternatives SANA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IPHA) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innate Pharma S.A. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Innate Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
